2016
Reassessment of Cardiac Function and Implantable Cardioverter-Defibrillator Use Among Medicare Patients With Low Ejection Fraction After Myocardial Infarction
Pokorney SD, Miller AL, Chen AY, Thomas L, Fonarow GC, de Lemos JA, Al-Khatib SM, Velazquez EJ, Peterson ED, Wang TY. Reassessment of Cardiac Function and Implantable Cardioverter-Defibrillator Use Among Medicare Patients With Low Ejection Fraction After Myocardial Infarction. Circulation 2016, 135: 38-47. PMID: 27881561, DOI: 10.1161/circulationaha.116.022359.Peer-Reviewed Original ResearchMeSH KeywordsAgedDatabases, FactualDefibrillators, ImplantableFemaleHeart VentriclesHumansMagnetic Resonance ImagingMaleMedicareMyocardial InfarctionMyocardial RevascularizationProportional Hazards ModelsRegistriesRetrospective StudiesStroke VolumeSurvival RateTomography, X-Ray ComputedUltrasonographyUnited StatesConceptsLow ejection fractionEjection fractionICD implantationMyocardial infarctionMI admissionsRevascularization statusImplantable cardioverter-defibrillator (ICD) useACTION Registry-GWTGICD implantation ratesMultivariable Cox modelPost-MI patientsYears of ageImplantation rateCardiac functionMedicare patientsCox modelPatientsAdmissionHigher likelihoodInfarctionImplantationAssociationYearsStatusICD
2010
The inter‐relationship of diabetes and left ventricular systolic function on outcome after high‐risk myocardial infarction
Shah AM, Uno H, Køber L, Velazquez EJ, Maggioni AP, MacDonald MR, Petrie MC, McMurray JJ, Califf RM, Pfeffer MA, Solomon SD. The inter‐relationship of diabetes and left ventricular systolic function on outcome after high‐risk myocardial infarction. European Journal Of Heart Failure 2010, 12: 1229-1237. PMID: 20965879, DOI: 10.1093/eurjhf/hfq179.Peer-Reviewed Original ResearchConceptsLeft ventricular ejection fractionRecurrent myocardial infarctionHF hospitalizationRisk of deathMyocardial infarctionCause mortalityHigh riskSpectrum of LVEFHigh-risk post-MI patientsBaseline left ventricular ejection fractionHigher left ventricular ejection fractionHigh-risk myocardial infarctionAcute Myocardial Infarction trialCox proportional hazards modelPost-MI populationHeart failure hospitalizationMyocardial Infarction trialNon-diabetic patientsVentricular systolic functionVentricular ejection fractionPost-MI patientsAcute myocardial infarctionPotent risk factorProportional hazards modelFailure hospitalizationFatal myocardial rupture after acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: The VALsartan In Acute myocardial iNfarcTion Trial (VALIANT)
Shamshad F, Kenchaiah S, Finn PV, Soler-Soler J, McMurray JJ, Velazquez EJ, Maggioni AP, Califf RM, Swedberg K, Kober L, Belenkov Y, Varshavsky S, Pfeffer MA, Solomon SD, Investigators F. Fatal myocardial rupture after acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: The VALsartan In Acute myocardial iNfarcTion Trial (VALIANT). American Heart Journal 2010, 160: 145-151. PMID: 20598985, DOI: 10.1016/j.ahj.2010.02.037.Peer-Reviewed Original ResearchConceptsQ-wave myocardial infarctionMyocardial infarctionMyocardial ruptureClinical end-point committeeHigh-risk myocardial infarctionAcute Myocardial Infarction trialEnd-point committeeNonfatal cardiovascular eventsPresence of hemopericardiumQualifying MIMyocardial Infarction trialHigh-risk patientsGlomerular filtration ratePost-MI patientsAcute myocardial infarctionInferior myocardial infarctionDirect surgical visualizationKillip classCardiovascular eventsDiuretic useOral anticoagulantsVentricular dysfunctionClinical characteristicsFatal complicationHeart failure
2009
Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial
Moukarbel GV, Signorovitch JE, Pfeffer MA, McMurray JJ, White HD, Maggioni AP, Velazquez EJ, Califf RM, Scheiman JM, Solomon SD. Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial. European Heart Journal 2009, 30: 2226-2232. PMID: 19556260, DOI: 10.1093/eurheartj/ehp256.Peer-Reviewed Original ResearchConceptsRisk factorsGastrointestinal bleedingGI bleedingWorse New York Heart Association classNew York Heart Association classAcute Myocardial Infarction trialPost-myocardial infarction patientsAdditional antiplatelet drugsProfound risk factorRate of GIAdjusted hazard ratioDual antiplatelet therapyMultivariable Cox modelMyocardial Infarction trialDual antiplatelet agentsLeft ventricular dysfunctionGlomerular filtration rateHigh-risk survivorsUse of antiplateletPost-MI patientsRisk of deathPotential risk factorsNon-white racePresent secondary analysisOccurrence of GI
2008
Predictors of the first heart failure hospitalization in patients who are stable survivors of myocardial infarction complicated by pulmonary congestion and/or left ventricular dysfunction: a VALIANT study
Lewis EF, Velazquez EJ, Solomon SD, Hellkamp AS, McMurray JJ, Mathias J, Rouleau JL, Maggioni AP, Swedberg K, Kober L, White H, Dalby AJ, Francis GS, Zannad F, Califf RM, Pfeffer MA. Predictors of the first heart failure hospitalization in patients who are stable survivors of myocardial infarction complicated by pulmonary congestion and/or left ventricular dysfunction: a VALIANT study. European Heart Journal 2008, 29: 748-756. PMID: 18308687, DOI: 10.1093/eurheartj/ehn062.Peer-Reviewed Original ResearchConceptsHeart failure hospitalizationMyocardial infarctionFailure hospitalizationHigh-risk acute myocardial infarctionFirst heart failure hospitalizationHigh-risk myocardial infarctionStable post-MI patientsIndex myocardial infarctionRecurrent myocardial infarctionPrior myocardial infarctionLong-term survivorsPost-MI patientsRisk of deathAcute myocardial infarctionOnset of HFAntecedent diabetesTime-dependent fashionVALIANT studyCardiovascular deathInitial hospitalizationVentricular dysfunctionMost patientsRenal functionIndependent predictorsPrognostic factors
2006
Use of Valsartan in Post-Myocardial Infarction and Heart Failure Patients
Liu PP, Maggioni A, Velazquez EJ. Use of Valsartan in Post-Myocardial Infarction and Heart Failure Patients. Journal Of The Renin-Angiotensin-Aldosterone System 2006, 7: s19-s22. PMID: 16986231, DOI: 10.3317/jraas.2006.019.Peer-Reviewed Original ResearchConceptsAng II receptor blockersHeart failureLV dysfunctionMyocardial infarctionStrong therapeutic rationaleUse of valsartanII receptor blockersLeft ventricular dysfunctionHeart failure patientsPost-MI patientsMain effector mechanismPost-myocardial infarctionLarge-scale trialsRAAS blockadeAldosterone systemReceptor blockersVentricular dysfunctionAssociated morbidityFailure patientsFrequent complicationSuch patientsACE inhibitorsSignificant morbiditySuch therapyDisease progression